mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC. - sprookjes - yvandenbroek - TriplyDB

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

http://www.wikidata.org/entity/Q37269265

about

Impact of HPV infection on oral squamous cell carcinoma.Neuroimmune mechanisms of behavioral alterations in a syngeneic murine model of human papilloma virus-related head and neck cancer.Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells mTOR co-targeting strategies for head and neck cancer therapy Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner.mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer

P2860

Q37718270-4FC72408-359E-47A5-A5CC-CDE5F9018352 Q38929870-965990A1-CF1B-40B8-A8F6-EA121B0432C3 Q42172217-E7B84189-51F6-4643-B2B1-3250D91615D7 Q42363764-03BDAADF-04D8-4F40-AD20-A0FBAD174696 Q46238476-6D78CE93-7666-4638-8F21-1A1581526E24 Q55223142-9A93EB5A-79AE-46F0-97BA-B3E6E97A467F Q57450687-95DFC9EB-9C90-459D-B898-D818FFF9DA50

P2860

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

http://www.wikidata.org/entity/Q37269265

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@en

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@nl

type

label

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@en

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@nl

prefLabel

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@en

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@nl

P1433

Q37269265-581DF86C-F1D2-4491-9263-12BF09A0591E

P1476

Q37269265-C276AB6D-1F92-4C11-B2FC-41983EE38E57

P2093

Q37269265-0E5CFAEB-4CEE-47A7-9B34-20B02D815DEE

Q37269265-4125D3B7-501F-4173-BC79-B0AE6D9A1A38

Q37269265-4FD19FD8-D1ED-44F0-98A7-328CBBC0F5F8

Q37269265-8F93589C-5A79-42C0-BAB6-3D4B99FD0036

Q37269265-98E4AE8B-ED92-4041-8EEE-51269FA3E561

Q37269265-B97594B4-3CFB-48BE-9EAA-4151B91F0CEC

Q37269265-C70621BE-E28E-4EE2-A4C7-7CE81BB1AC2D

P2860

Q37269265-1A8135BE-8348-4C5C-8602-D6AC6E7707A2

Q37269265-2D652873-75E0-4BA9-B388-0627CAC245E0

Q37269265-2FEE3A20-F75D-4BFC-A929-E4947771BA97

Q37269265-375C694E-10E6-474A-B73F-E5B43D86D5B3

Q37269265-39D9AFDE-084B-40C6-9427-8755A13856BA

Q37269265-3FF36FCE-BC63-4F3D-99E3-69927846EA6F

Q37269265-47DDCB15-F604-4453-964D-731A547AF968

Q37269265-4953CAAC-32ED-4294-8713-90AFCFC6F2CD

Q37269265-5D16D3DD-EC11-444B-AC48-5B2097AD04FE

Q37269265-6280B0CA-424E-45C1-AC8E-FF21F7AE7BA2

P304

Q37269265-29AAC0F0-1F33-4955-9CE3-DB184EF2EAA7

P31

Q37269265-293DD204-5454-4C09-BE69-CEA48FEA9B26

P356

Q37269265-7D363455-812F-4E5B-A639-1F0FE7BE3D0B

P407

Q37269265-809B4173-026F-4728-A44F-0DEA59BC5985

P433

Q37269265-84207F1D-2BA7-4EE3-B8BC-329D5815F767

P478

Q37269265-9A11B3EE-A113-48CF-9FF9-9DD847BDA00D

P577

Q37269265-FB9E66BD-B382-4572-9E18-6DD625570352

P698

Q37269265-B0E015A3-E397-499C-B6CC-78DC710E7B11

P932

Q37269265-F952399D-D9C2-458B-9BEF-D8E13406C205

P356

ONCOTARGET.8286

P1433

P1476

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

@en

P2093

Daniel W Vermeer

http://www.w3.org/2001/XMLSchema#string

John H Lee

http://www.w3.org/2001/XMLSchema#string

Joseph D Coppock

http://www.w3.org/2001/XMLSchema#string

Kimberly M Lee

http://www.w3.org/2001/XMLSchema#string

Paola D Vermeer

http://www.w3.org/2001/XMLSchema#string

W Keith Miskimins

http://www.w3.org/2001/XMLSchema#string

William C Spanos

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR signaling in growth control and disease

Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing

The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium.

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

Impact of HPV in Oropharyngeal Cancer.

Mammalian target of rapamycin and head and neck squamous cell carcinoma

Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets

Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.

Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

P304

24228-24241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8286

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27015118

http://www.w3.org/2001/XMLSchema#string

P932

5029697

http://www.w3.org/2001/XMLSchema#string